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ABSTRACT
lhis study approaches the question of whether angio­
tensin II (Angll) and transforming growth factor ¡3 
(TGF-jS) are important mediators for mesangial hepa­
ran sulfate proteoglycan (HSPG) production. This 
might explain the beneficial effects of angiotensin- 
converting enzyme inhibitors observed in several kid­
ney diseases independent from their hemodynamic 
effects. Metaboiic-iabeling studies revealed that Angil 
induced a decrease of HSPG synthesis with decreases 
in N-sulfation of the glycosaminoglycan side chains. 
ELISA measurements with a heparan sulfate (HS)-spe- 
cific monoclonal antibody confirmed that Angll de­
creased HS production. Angll increased TGF-j3 pro­
duction in a dose-dependent fashion. Specific mRNA 
for the large basement membrane HSPG (perlecan) 
decreased, whereas mRNA for TGF-(3 increased after 
incubation with Angll. Blockade of the Subtype 1 
Ang-ii receptor (ATR1) reversed both the effects of 
Angll on HSPG and IGF-¡3 production. Coincubafion of 
Ihe mesangial cells with neutralizing antibodies 
against TGF-/3 significantly reduced the production of
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HS as compared with control and Angll. These results 
indicate that the decrease in HS synthesis induced by 
Angll is not mediated by an increase in TGF-/3, but on 
the contrary, the increase in TGF-/3 partially counter­
acts the Inhibition of HS production by Angll. Consid­
ering the important role of HSPG in maintaining the 
glomerular charge barrier, ceil proliferation, and ma­
trix interaction, downregulation of the production of 
this molecule by increased local Angll concentra­
tions could have important consequences, such as 
albuminuria and matrix expansion.
Key Words: Giomeruiar diseases, extracellular matrix, glomer­
ular mesanglum, angiotensin converting enzyme, heparan 
sulfate proteoglycan
S everal lines of evidence suggest that heparan sulfate proteoglycan (HSPG) may be involved In the functional and anatomical changes seen in glo­merular diseases such as systemic lupus erythemato­sus (1), congenital nephrotic syndrome (2), and dia­betic nephropathy (DN) (1,3), such as proteinuria and mesangial expansion. Another indication for the role of glycosaminoglycans (GAG) in proteinuria comes from recent data showing that treatment with GAG can reduce proteinuria both in experimental (4) and human DN (5*6). HSPG is strongly negatively charged as a result of sulfate and carboxyl groups distributed along the heparan sulfate (HS)-GAG side chain. In several animal models of glomerular diseases (7-9) and in patients with DN (10), angiotensin-converting enzyme (ACE) inhibitors were found to decrease pro­teinuria and glomerulosclerosis regardless of a change in glomerular hemodynamics. This raises the possibility that, apart from its hemodynamic action, angiotensin II (Angll) may have direct effects at the cellular level, A likely target in the kidney would be the mesangial cells (MC) because these cells are known to express Angll receptors (11-13). Indeed, Kagami et a i  (14) have found that Angll, separate from its hemody­namic effects, stimulates rat MC synthesis of several matrix proteins. This effect was mediated through the induction of transforming growth factor-/3 (TGF-/3). TGF-J3 is an important mediator of cell growth and matrix production and degradation (15-18) and seems to have a central role in the accumulation of patho­logical extracellular matrix in glomerulonephritis (19- 23). Thus, the beneficial effects of ACE inhibitors in glomerular diseases could be partially explained by
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the inhibition of the actions of Angll on matrix pro­duction. However, the question remains: Through which mechanism can these ACE inhibitors induce a decrease in proteinuria? The antiproteinuric effect could not be explained by a change in glomerular hemodynamics (24). Considering the role of HSPG in the permeability of the glomerular basement mem­brane (GBM), cell proliferation and matrix interaction, effects of Angll on its synthesis could play an impor­tant role in the pathogenesis of several glomerular diseases. Therefore, we studied the effects of Angll on the production of HSPG by human adult MC, analyzed by which Angll receptor these effects were mediated, and determined the role of TGF-/3 in this respect. These studies might help explain the decreased ex­pression of HS (1-3,25) and increased expression of TGF-/3 (20,26) observed histologically in glomerular diseases such as DN.
METHODS 
Cell Culture
MC were cultured from glomeruli obtained from normal human adult kidneys not suitable for transplantation, by using methods described previously (27,28). In brief, MC 
were sub cultured from “hillocks” usually appearing after 3 wk of outgrowth from the glomeruli, in 24-well plates 
(Greiner, Frickenhausen, Germany} in Dulbecco modified Eagle medium (DMEM) supplemented with 10% heat-inacti- 
vated fetal calf serum (A FCS) (Hyclone Laboratories Inc., Logan, UT). The cells were fully characterized by their cell 
morphology (spindle-shaped, in multilayers) and uniform fluorescence with fluorescein isothiocyanate-phalloidin for actin, vimentin, and absence of fluorescence, by using mono­clonal antibodies against von Willebrand factor, TN9, TN10 (29), cytokeratin, and desmin. For experimental purposes, 
cells were grown in DMEM with 10% A FCS for 24 h, and 
subsequently made quiescent by placement in DMEM with0.5% A FCS for 24 h. They were then cultured for a 3-day period in medium alone or containing the following additives: Angll (10~6 to 10"11 M; Sigma Chemical Co.. St. Louis, MO) 
alone, supplemented with either the specific nonpeptide Angll-receptor Type I antagonist (ATR1) losartan (DviP 753, 10~5 M; kindly provided by the DuPont Company, Wilming­ton, DE) or a Angll-receptor Type II antagonist (ATR2) (PD123,319-012 IB, 10“s M; kindly provided by Park Davis, Ann Arbor, MI). Additional experiments were performed us­
ing neutralizing anti-human TGF-/31,2,3 monoclonal anti­bodies (2G7) (30) or human recombinant TGF-J31 (R&D Sys­tems, Abingdon, UK). Cell counts were performed at the beginning and end of each experiment in triplicate by using a 
Coulter Counter (Coulter Electronics, Mijdrecht, The Nether­lands). The cells were cultured in either 12-well plates 
(40,000 cells/well) (ELISA) or T75 plates (metabolic labeling/ RNA isolation).
Metabolic Labeling
Na23SS04 and 3H-glucosamIne labeling of MC cells wasperformed as previously described (28). In brief, MC were 
cultured in T75 flasks until confluence and maintained 
overnight with DMEM supplemented with 2% A FCS. Media 
were replaced by sulfate-free DMEM with 2% (dialyzed) A FCS and labeled for 24 h at 37°C using 100 juCi/mL Na235S 0 4 (carrier-free; New England Nuclear, Boston, MA)
and 25 /¿Ci/mL 3H-glucosamine (Amersham International, 
UK). Cell labeling was performed in media alone or supple­
mented with Angll (10“6 M). After 24 h, the cell media were 
separated from the cells. The cells were washed three times with cold phosphate-buffered saline (PBS) and these washes 
were added to the media fraction. Cells were scraped into an 
extraction buffer containing 4 M guanidine HC1 at 4°C and a 
cocktail containing the pro tease inhibitors 10 mM EDTA and 
5 mM phenylmethyl sulfonyl fluoride (PMSF), 2 mM benza- 
midine, 50 mM e-aminocaproic acid, 0.5 U/mL aprotinin, 
and 5 mM iodoacetamide (all from Sigma). Both the cell media and cell extracts were dialyzed extensively at 4°C 
against 0.5 M sodium acetate, pH 5.8, with the protease- 
inhibitors cocktail. The fractions were finally dialyzed against 
diethylaminoethyl (DEAE) buffer containing 6 M urea, 50 
mM Tris, 0.2% chaps with protease-inhibitors cocktail, pH 
7.0, and separated on a 5-mL DEAE anion exchange chro­
matography column. The labeled material was finally sepa­rated using HPLC with a DEAE anion exchange 75 X 7.5 mm 
Bio-Gel TSK DEAE-5PW HPLC column (Biorad, Richmond, 
CA). The bound material eluted with an increasing NaCl 
gradient in DEAE buffer (0,1 to 1.0 M), at a flow rate of 1 
mL/min, with 1.0-mL fractions collected. The conductivity of 
each fraction was measured using a CDM3 radiometer con­
ductivity meter (Copenhagen, Denmark) and the 35S and 3H 
radioactivity was measured by adding aliquots of the frac­
tions to a fluorophore Ultima Gold (Packard Instrument B,V. 
Chemical Operations, Groningen, The Netherlands). The sep­
aration protocol resulted in different proteoglycan peaks. 
These peaks were dialyzed against distilled water, freeze- dried, and stored at -20°C until use. Characterization of the 
different macromolecules were performed as described pre- 
vioiisly (28). In brief, each of the pooled fractions were treated 
with alkaline-/3 elimination in 0.75 M NaOH and 20 mM 
sodium borohydride (NaBH4) for 1 h at 72°C (31), followed by 
separation on a G50 size separation column run in 0,5 M 
sodium acetate buffer containing 0.2% chaps and protease- 
inhibitors cocktail, pH 7.0. The G50 column was presatu­
rated with 1 mg/mL heparin and 10 mg/mL BSA. The void 
volume was tested for its sensitivity to chondroitinase ABC 
(Ch-ABC) (2.5 mU), chondroitinase AC (Ch-AC) (2.5 mU), and 
heparitinase (2.5 mU) (32) and analyzed by electrophoresis in 
a composite gel of 0.6% agarose-1.8% polyacrylamide as 
described (28). Identification of the 35S -/3H- glycosaminogly- 
cans was determined by the following criteria: (1) molecules 
with sensitivity to heparitinase without sensitivity to Ch-ABC 
or Ch-AC are designated as heparan sulfate; (2) molecules 
with sensitivity to Ch-ABC without sensitivity to Ch-AC were designated as dermatan sulfate; and (3) molecules equally 
sensitive to both Ch-ABC and Ch-AC were referred to as chondroitin sulfate.
Distribution of Oligosaccharides Formed by 
Nitrous Acid Cleavage
Heparan sulfate proteoglycans isolated from the cell media 
and cell extract of MC were treated with papain (1 mg/mL) for 
18 h at 55DC, and subsequently he at-inactivated at 100°C 
(33). The material was centrifuged (3000 rpm) to spin down 
the papain. The supernatant was cleaved with HN02 at pH1.5, and separated into disaccharides, tetrasaccharides, and 
higher oligosaccharides by gel filtration on a G25 sephadex 
size separation column (0.95 X 100 cm) in 0.5 M NH4HC03 (2 
mL/h) (34).
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Heparan Sulfate ELISA
MC were cultured in 12~well plates as described above. HS 
was detected by a inhibition ELISA using mouse anti-GBM 
HS-GAG side-chain-specific antibodies previously described by van den Born et al (25). HS production of three different cell lines were measured in triplicate.
TGF-/3 Bioassay and ELISA
MC were cultured in 12-well plates and cultured as de­scribed above. The cell media were analyzed for latent and active TGF-0. TGF-/3 production of three different cell lines 
were measured in triplicate. Activation of TGF-jS was per­formed by heating the samples in a water bath for 10 min at 8 0 °C, followed by immediately cooling in ice water. Latent 
and active TGF-/3 was measured by the inhibition of growth of the mink-lung cell line CCL-64 (American Tisstie Type Col­
lection, Rockville, MD). Growth inhibition was measured as the decreased uptake of neutral red (35), Specificity for TGF-j8 was demonstrated by the full reversal of any inhibitory 
activity by the addition of a monoclonal antibody specifically recognizing human TGF-J3 1,2,3 (2G7) (30). Secreted TGF-/3 in the medium was also measured by sandwich ELISA using human recombinant TGF-/31 (rTGF-j3) as standard for every 
plate. Activation of TGF-jS was performed by pH. In brief, mouse anti-human TGF-/3 (2G7) (2 jug/mL in PBS) was allowed to adhere to 96-well plates for 1 h at 37°C and overnight at 4°C. After extensive washing and a blocking step for 1 h with PBS, 0.2% Tween-20, 2% BSA, the samples were 
added in duplicate to the wells for 2 h at room temperature (RT). After washing chicken anti-TGF-/3 coupled to didoxyge- nine (DIG), antibodies were incubated for 1 h at RT. Plates 
were washed and anti-DIG F(ab)'2 conjugated to horseradish peroxidase was allowed to bind for 1 h at RT. Peroxidase reactivity was visualized by addition of the peroxidase sub­strate ABTS (2,2'-azino-bis-3-ethylbenzthiazolin; Sigma) 
prepared in 100 mM citrate, 100 mM phosphate buffer, pH 4.2. Optical density was measured at 415 nm.
Northern Blot Analysis
Total RNA was isolated with RNAzol (Campro Scientific, Veenendaal, The Netherlands) from MC grown in T75 flasks as described above. Fifteen micrograms of total RNA were 
separated on a 1% (wt/vol) agarose gel containing 2.2 M formaldehyde pH 4.0, 3-[N-Morpholino]propanesulfonic acid (MOPS) buffer (0.02 M MOPS, pH 7.0, 8 mM sodium acetate, 1 mM EDTA, pH 8.0) and blotted to reinforced nitrocellulose 
(Schleicher & Schuell, Keene, NH) as described by Sambroolc et  al (36). Prehybridization and hybridization was done in a Hybridization mix consisting of 0.5 M sodium phosphate buffer, pH 7,2, 7% (wt/vol) sodium dodecyl sulfate, 1% 
(wt/vol) BSA (Sigma) and 1 mM EDTA, 100 /jg/mL single­stranded herring sperm DNA as described by Church and Gilbert (37). After 2 h of prehybridization at 65°C, a cDNA probe specific for TGF-/31 (Number X02812) obtained from the American Tissue Type Collection (Rockville, MD) or a 
cDNA probe (Clone 16.7) specific for the large basement membrane HSPG perlecan (38), radiolabeled with (a- 32P)dCTP by random-primed labeling was added and the blot 
was hybridized overnight at 65°C. After hybridization, the blots were washed for 30 min with three buffers with de­
creasing molarity of sodium phosphate buffer (0.5, 0.25, andO.l M, respectively [pH 7.2]) 1% sodium dodecyl sulfate and1 mM EDTA. In addition to ethidium bromide staining, 
control hybridization for equal loading was performed using 
a 0.5-ldlobase (kb) glyceraldehyde-3-phosphate dehydroge­
nase (Number 78105, American Tissue Type Collection). The intensity and area of the bands on the autoradiograms were determined with an Ultroscan XL (LKB, Woerden, The Neth­
erlands).
Statistical Analysis
The data of control and experimental groups are expressed 
as mean ± SD. Statistical analysis was performed using the t test and a analysis of variance test for multiple group comparison. A P value of < 0.05 used to determine signifi­
cance,
RESULTS 
Effect of Angll on Proteoglycans Synthesis by 
Mesangial Cells
HPLC-DEAE anion exchange chromatography of the Na235S 0 4 and 3H-ghAcosamine-labeled proteoglycans resulted in several peaks. The proteoglycan-contain­ing peaks were pooled as indicated in Figure 1. The peaks eluting at milliSiemens lower than 15 did not contain any type of proteoglycans and were therefore not relevant for this study. Enzymatic analysis fol­lowed by separation on a composite gel of 0.6% aga- rose-1.8% polyacrylamide revealed that Peak I was only sensitive to heparitinase and therefore consisted of HS (Figure 2, Lanes 1 to 3). Peaks II and III (only obtained from the cell media of Angll-treated cells) were only sensitive to chondroitinase ABC and not AC (data for chondroitinase AC are not shown) and there­fore consisted of dermatan sulfate (DS) (Figure 2, Lanes 4 to 6 and 7 to 9, respectively). Total cpm was calculated from each peak fraction (I and II) and corrected for cell number. For comparison, the cpm/ cell per fraction of Angll-treated cells were divided by the cpm/cell per fraction of control cells, which re­sulted in the data presented in Table 1. These data therefore represent the mean percentage of Angll- treated cells compared with control (N = 2) of each labeled proteoglycan. Analyses of the cell media re­vealed a 26% decrease in 35S-labeled and 35% de­crease in 3H-labeled HS/cell. For both the 35S- and 3H-labeled DS (Peaks II and III for Angll-treated cells, compared with Peak II of control cells), a 80% decrease was found, Analysis of the cell extract revealed a 53% decrease for the 35S- and 60% decrease for the 3H- labeled HS, whereas the 35S- and 3H-labeled DS re­mained unaltered.
Effect of Angll on the Distribution of 
Oligosaccharides Formed by Nitrous Acid 
Cleavage
HS isolated from the cell media and cell extract of MC grown in the absence or presence of Angll were separated as described in the Methods section, Ni­trous acid treatment at pH 1.5 separates heparan sulfate in disaccharides (Peak III), tetrasaccharides (Peak II), and larger oligosaccharides (Peak I). Peaks I, II, and III were analyzed for 3H-glucosamine (Figure 3,
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Figure 1. HPLC-DEAE (diethylaminoethyl) chromatography of Na235S04 (A, B, E, F)/3H-glucosamine (C, D, G, H)-labeled 
macromolecules synthesized by human MC cultured in the absence or presence of Ang II. Celis were labeled a$ described and 
the cell media and cell layers were harvested and extracted. The figure shows the profiles (solid line) of the macromolecules 
from the cell media (A-D) and cell extract (E-H) that were eluted with a NaCI gradient. The salt gradient (dotted line) was 
expressed in milllSiemens (mS).
Table 2), When no discernible peak was obtained, we calculated the cpm in the fraction that eluted at the same kav as the original peak fraction {represents molecules with the same molecular weight). For the cell media, approximately 44% [27% plus 17%) of the 3H-labeled HS obtained from MC grown in control media cleaved into disaccharides and tetrasacchar- ides, whereas 56% was either not cleaved at all or cleaved into larger fragments. HS obtained from cell
media of MC grown in the presence of Angll resulted in a different cleavage pattern i.e., disaccharides and tetrasaccharides (22%) and larger fragments (78%). Analysis of the cell extract showed a changed cleavage pattern when MC were cocultured with AngIL Com­pared with control, a decrease from 34 to 26% of disaccharides and tetrasaccharides and a increase from 66 to 74% of the larger or oligosaccharide frag­ments was observed.
1018 Volume 7 • Number 7 • 1996
van Det et al
1 2 3 4 5 6  7 8 9 2500
• ! W .
- —tifi.h.
. < : 
. <4 \
4^  •» *> s //:io  - s..^  •.
Case ABC 
Hep'ase
Figure 2. Characterization of the different proteoglycans 
produced by MC. Cells were labeled as described and the 
different proteoglycans were separated using an HPLC an­
ion exchange column. The proteoglycan-containing peaks 
were pooled as Indicated in Fjgure IB. Shown here are the 
enzymatic analyses performed on Peak! (Lanes 1 to 3), Peak 
II (Lanes 4 to 6), and Peak III (Lanes 7 to 9) obtained from the 
cell media of MC cocultured with Anglf, The different pooled 
fractions were separated on a 0.6% agarose-1.8% polyacryl­
amide gel before (Lanes 1, 4, 7) and after treatment with 
either heparitinase (Lanes 3, 6, 9) or chondroltmase ABC 
(Lanes 2, 5, 8).
TABLE 1.  Quantitative changes In proteoglycansa
Cell Group
HS (Peak 1) DS (Peaks 1 plus
Hi)
Cell
Medium
Cell
Extract
Cell
Medium
Cell
Extract
35S04-Labeled
Macromolecules
3H-Labeled
Macromolecules
26.4%
34.8%
53.3%
59.6%
80.9%
80.4%
106%
148%
a Total cpm was calculated from each peak fraction (Figure 1) and 
corrected for cell number. The data represent the mean percentage 
of Angll-treated cells compared with control (N -  2),
Effect of Angll on the Production of HS and 
TGF-/3
To determine whether Angll had an effect on the production of HS and TGF-/3, MC were grown for 3 days with increasing concentrations of Angll (10“ 11 to 10"6 M). Increasing the concentration of Angll re­sulted in a significant decrease (2- to 8-fold; P < 0.05) in excreted HS in the media from 10“9 M and higher and a significant increase in excreted active TGF-|3 (2- to 6-fold; P <  0.05) from 10"8 M and higher (Figure 4). To investigate through which receptor the effects of Angll were mediated, we cultured MC with Angll {10"6 M) alone or with the addition of either the ATR1 antagonist losartan, or the ATR2 antagonist PD 123,319. The decrease in HS production and in-
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Figure 3. G25 sephadex fractionation of HS deamination 
products obtained from MC. HS excreted in the cell media 
and isolated from the extract of MC grown in the presence 
(bold solid line) or absence (solid line) of Angll was treated 
with nitrous acid (pH 1.5), The products were chromato­
graphed on a 0.95 x 100-cm G25 sephadex column in 0,5 M 
NH4HC03. Fractions of 1 mL were collected and analyzed for 
3H-glycosamlnog!ycan. Fractions were pooled as indicated 
by the vertical bars. Fraction III represents the disaccharides, 
II the tetrasaccharides, and I the larger oligosaccharides.
TABLE 2. Distribution of oligosaccharides formed by 
nitrous acid cleavage0
Cell Media Cell Extract
Control Angll Control Angll
Disaccharides (lll)b 27 11 0 2
Tetrasaccharides (ll)b 17 11 34 24
Larger or Oligosaccharides (l)b 56 78 66 74
a Heparan sulfate excreted in the ceil media or Isolated from the 
extract of MC were cleaved by nitrous acid (pH 1.5), The obtained 
fragments were separated by G25 gel-filtratlon chromatography. 
Relative distribution Is calculated In total % glucosamine. 
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Figure 4. Effect of increasing concentrations of Angll on the 
production of TGF-/3 and HS by MC in vitro. MC were cultured 
for 3 days in the presence or absence of increasing concen­
trations of Angll. Excreted HS is expressed as /xg/106 cells per 
72 h and TGF-0 Is expressed as ng/106 cells per 72 h. * P < 
0.05 (N = 3).
crease in TGF-jS production induced by Angll were abolished by the ATR1 antagonist losartan but not by the ATR2 antagonist PD 123,319 (Figure 5, A and B). The effects of Angll on MC were not the result of a
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Figure 5. Effect of colncubatlon with TGF-/3 antibody and 
iosartan or PD123,319 on (A) the HS and (B) the TGF-j3 
production by control MC (shaded bars) and Angll- 
stimuiated (black bars) MC. MC were cultured in 12-well 
plates until confluence and subsequently cocultured for 3 
days In media alone or supplemented with Angll (10~6 M) 
with either 10~5 M Iosartan, 10~5 M PD 123,319, or 25 /xg/mLof 
anti TGF-jS antibody. Mouse IgG (25 ju,g/mL) was used as 
control antibody. HS is expressed as /¿g/106 cells per 72 h, 
TGF-/3 is expressed as ng/106 cells per 72 h. * P < 0,05 (N = 3).
general change of protein production, because no change in the production of the complement compo­nent factor H was measured (control, 144.7 ± 3.4 ng/106 cells versus Angll-treated cells, 159.9 ± 8.7 ng/106 cells). Furthermore, no differences in cell numbers were found and all concentrations were cor­rected for cell number. The viability of the cells was unaltered because no detectable levels of lactate de­hydrogenase were found in the medium (data not shown). TGF-j3 was measured using both a bioassay (Figure 4 and 5B) and ELISA and gave similar results (ELISA: control, 1.91 ± 0*28 ng/106 cells uersus Angll-treated ceils, 20.73 ± 9.53 ng/106 cells; P <  0.05, JV = 3).
Effect of Coincubation with TGF-/3 Antibody or 
rTGF-/3 on the HS Production by Control and 
Angll-Stimulated Mesangial Cells
To investigate whether the effect of Angll on HS production by MC was mediated by the increased levels of TGFjS, control cells and Angll-treated cells were cocultured with neutralizing mouse anti-human TGF-/3 monoclonal antibodies (25 ¡jug/mL] or control mouse immunoglobulin G (IgG) (25 /xg/mL). Neutral­izing TGF-/3 antibodies significantly reduced the pro­duction of HS to undetectable levels (Figure 5A) in both control and Angll-treated cells. Control IgG an­tibodies had no effect on the HS production. Also, the addition of anti-TGF-/3 antibodies did not result in any differences in detection of HS. To assess whether TGF-/3 had a direct effect on the HS production, increasing concentrations of rTGF-/3 (0 to 50 ng/mL) were added to MC. rTGF-/3 induced a dose-dependent increase in HS production starting at a concentration of 12.5 ng/mL (Figure 6)
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Figure 6. Effect of increasing concentrations of human re­
combinant TGF-/3 on the HS production by MC. MC were 
cultured in 12-well piates until confluence and subsequently 
cocultured for 3 days in media alone or supplemented with 
increasing concentrations of rTGF-/3 (0 to 50 ng/mL). HS was 
measured in the HS inhibition ELISA and expressed as /¿g/lO6 
cells per 72 h. * P < 0,05 (N = 3).
The Effect of Angll on the Message RNA Levels 
of Perlecan and TGF-/3
Northern blot analysis revealed that Angll induced a decreased expression of perlecan (14 kb) and in­creased expression of TGF-/3 (2.5 kb) (Figure 7; Lanes 1 (control) versus Lane 2 (Angll)). The ATR2 antagonist (PD 123,319) reversed the decreasing effect of Angll on perlecan expression, whereas it had no effect on the increasing levels of TGF-j3 induced by Angll (Figure 7; Lane 3). The effects of Angll on the steady-state mRNA levels of perlecan and TGF-/3 were almost completely reversed by the ATR1 antagonist Iosartan (Figure 7; Lane 4). rTGF-/31 did not change the expression of either perlecan or TGF-j3 itself (Figure 7; Lane 5). Furthermore, anti-TGF-/3 antibodies decreased the perlecan expression compared with the mouse IgG control (Figure 7; Lanes 6 and 7, respectively). No effect was seen on the TGF-/3 expression itself (Figure 7; Lanes 6 and 7, respectively).
DISCUSSION
ACE inhibitors, which block the Angll generation, were found to decrease proteinuria and matrix expan­sion in several animal models of glomerular diseases and in patients with DN, independent of their hemo­dynamics, indicating a direct effect on glomerular cells (24). Some studies have suggested that Angll may adversely affect the glomerular filtration barrier, most likely by alteration of HSPG concentration/sul­fation, resulting in proteinuria (39-41).
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Figure 7. The effect of Angll on the mRNA levels of perlecan 
and TGF-/8. MC were cultured In T75 flasks until confluence 
and subsequently cocultured for 3 days in media alone 
(Lane I) or supplemented with Angl! (Lane 2), Angll + 
PD123,319 (Lane 3), or Angll 4- losartan (Lane 4). Lane 5 
represents cells cuitured with rTGF-/3 alone, Lane 6 represents 
antl-TGF-/3 alone, and Lane 7 represents control mouse IgG.
The study presented here demonstrates that Angll has an inhibitory effect on HS production and sulfa­tion by human adult MC and indeed suggest that ACE inhibitors might work by blocking the Angll genera­tion in the glomerulus, thereby normalizing the HSPG content. A similar phenomenon might occur with HSPG of the GBM and play a role in the glomerular charge barrier. Further experiments are necessary to substantiate this point. The inhibitory effect on HS production was specific, because it could be blocked by the ATR1 antagonist losartan. These observations could explain the observation that ACE inhibitors normalize the expression of HS in the GBM in adria- mycin nephropathy (42), The decrease in perlecan expression after coculture of MC with Angll suggest that changes also occur at the core protein level of HSPG.The beneficial contribution of ACE inhibitors on matrix expansion could be explained by the findings that Angll induces MC matrix production (14,43,44), Another explanation could be related to normalization of the interaction between HS and basic fibroblast growth factor {bFGF). HS was found to be obligatory for receptor binding and the mitogenic activity of bFGF (45-47). In fact, in human MC, heparin-like molecules were found to inhibit the stimulatory effects of bFGF on matrix production and proliferation (N.F. van Det et ah Inhibitory effects of glomerular heparan sulfate and heparin-like molecules on stimulation of mesangial cell proliferation and matrix production by basic fibroblast growth factor, submitted). This indi­cates that loss of HS from the extracellular matrix may
result in an altered biological activity of bFGF, result­ing in increased proliferation and matrix production. The observed decrease in N-sulfation could be rele­vant in this respect, because sulfation of HS was found to be important for the interaction with bFGF (46,47).
The effects of Angll on intraglomerular pressure can also lead to proteinuria and glomerulosclerosis (48). Although this alone does not completely explain the effects of ACE inhibitors, one explanation could be the role of the heparin/HS in the vasoregulatory control of blood pressure recently reviewed by Mandel et al (49). The fact that heparin downregulates the Angll-medi­ated vascular smooth muscle cell and MC contractile responses could indicate that inhibition of HS produc­tion by Angll amplifies this response and, therefore, the hemodynamic actions of Angll.Similar to the findings of Kagami et al (14), we found that Angll-treated MC resulted in increased levels of TGF-/3, which was induced by the actions of Angll on its ATRa receptor. However, unlike the effect of Angll on the matrix components fibronectin, biglycan, and collagen Type I production, the inhibitory effect of Angll on the HS production was not found to be regulated by the increased levels of TGF-/3. In fact, the increasing effects of Angll on TGF-/3 production par­tially counteract the inhibition of HS production, be­cause neutralizing TGF-/3 inhibit the HS production to almost undetectable levels. The effect of neutralizing anti-TGF-jS antibodies on the HS production was not the result of toxic effects on MC because no detectable LDH could be measured in the cell media (data not shown). Also, control IgG antibodies showed no stich  effects. A decrease in perlecan expression was also found after addition of neutralizing anti-TGF-/3 anti­bodies. These results suggest that the beneficial ef­fects of anti-TGF/31 antibodies on the extracellular matrix accumulation in experimental glomerulone­phritis (50) might also have some negative effects by downregulation of HS in the glomeruli. The apparent 
paradigms of too much or too little TGF-/3 on host defense discussed by Wahl (51) might therefore also be relevant to the discussion of the role of TGF-/3 in glomerular diseases.Evidence for a role of TGF-/3 in proteoglycan produc­tion has previously been described for biglycan and decorin (52,53). We found that rTGF-j31 stimulates HSPG production in a dose-dependent manner. No effect of rTGF-j31 on perlecan expression was found, 
indicative of a post-transcriptional regulation. Other researchers (53) did not find any effect of TGF-/3 on HSPG production when rat MC were used instead of human MC.The mechanisms underlying the effects of Angll have not been fully elucidated. Some reports claim that binding of Angll triggers a transmembrane signal linked to phospholipase D, and that this is dependent on protein kinase C activation (54-56).In conclusion, we have shown that Angll induces a quantitative (decreased HS) and qualitative (de-
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creased N-sulfation} change in HS production by MC and that this effect is not mediated by TGF-/3. The induced increased production of TGF-/3 by Angll coun­teracts the decrease of HS production. The intracellu­lar mechanisms underlying these effects still remain unclear, and should be examined in future studies. These observations put new light on the “dark side” of TGF-/3 in glomerular pathology, because, in contrast to earlier studies reporting proinflanimatory and pro- sclerotic effects, TGF-/3 might also be beneficial, be­cause of its effects on HSPG (perlecan) production.
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